X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3603) 3603
lung neoplasms - enzymology (2015) 2015
oncology (1899) 1899
carcinoma, non-small-cell lung - enzymology (1788) 1788
female (1677) 1677
male (1408) 1408
middle aged (1201) 1201
lung neoplasms - pathology (1156) 1156
cancer (1099) 1099
cell line, tumor (1087) 1087
aged (1039) 1039
animals (992) 992
carcinoma, non-small-cell lung - pathology (960) 960
lung neoplasms - genetics (923) 923
lung neoplasms - drug therapy (889) 889
carcinoma, non-small-cell lung - genetics (834) 834
carcinoma, non-small-cell lung - drug therapy (832) 832
adult (821) 821
lung cancer (756) 756
expression (754) 754
apoptosis (617) 617
prognosis (614) 614
immunohistochemistry (612) 612
carcinoma (586) 586
mice (569) 569
tumors (546) 546
cell biology (523) 523
mutation (511) 511
lung cancer, non-small cell (487) 487
chemotherapy (485) 485
gene expression regulation, neoplastic (465) 465
research (457) 457
aged, 80 and over (456) 456
metastasis (456) 456
proteins (410) 410
antineoplastic agents - pharmacology (388) 388
analysis (379) 379
protein kinase inhibitors - therapeutic use (377) 377
carcinoma, squamous cell - enzymology (375) 375
signal transduction (375) 375
non-small cell lung cancer (369) 369
gene expression (366) 366
antineoplastic agents - therapeutic use (364) 364
kinases (360) 360
phosphorylation (349) 349
mice, nude (347) 347
adenocarcinoma - enzymology (342) 342
genetic aspects (340) 340
survival (336) 336
care and treatment (334) 334
apoptosis - drug effects (331) 331
activation (329) 329
breast-cancer (326) 326
cell proliferation (323) 323
biochemistry & molecular biology (314) 314
neoplasm staging (312) 312
protein kinase inhibitors - pharmacology (312) 312
pathology (302) 302
research article (301) 301
cell proliferation - drug effects (278) 278
growth (274) 274
treatment outcome (273) 273
adenocarcinoma (271) 271
gefitinib (266) 266
health aspects (265) 265
medicine (265) 265
lung neoplasms - metabolism (264) 264
time factors (263) 263
tumor cells, cultured (261) 261
neoplasm invasiveness (257) 257
receptor, epidermal growth factor - genetics (256) 256
xenograft model antitumor assays (256) 256
blotting, western (251) 251
development and progression (249) 249
receptor, epidermal growth factor - antagonists & inhibitors (249) 249
biomarkers, tumor - metabolism (247) 247
enzymes (247) 247
lung-cancer (247) 247
pharmacology & pharmacy (245) 245
transfection (241) 241
signal transduction - drug effects (238) 238
inhibition (236) 236
neoplasms - enzymology (236) 236
carcinoma, non-small-cell lung - metabolism (231) 231
multidisciplinary sciences (225) 225
up-regulation (223) 223
disease-free survival (215) 215
respiratory system (214) 214
carcinoma, squamous cell - pathology (209) 209
drug resistance, neoplasm (209) 209
cancer therapies (206) 206
gene (204) 204
reverse transcriptase polymerase chain reaction (200) 200
cell lung-cancer (199) 199
angiogenesis (198) 198
cancer research (197) 197
science (197) 197
disease progression (195) 195
lung neoplasms - mortality (195) 195
respiratory tract diseases (194) 194
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3670) 3670
Chinese (91) 91
Japanese (15) 15
French (12) 12
Polish (4) 4
Russian (3) 3
Hungarian (2) 2
Spanish (2) 2
Czech (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2015, Volume 125, Issue 2, pp. 687 - 698
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie and the Associazione Italiana Oncologia Toracica and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
Cancer, ISSN 0008-543X, 12/2013, Volume 119, Issue 24, pp. 4325 - 4332
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2014, Volume 124, Issue 1, pp. 117 - 128
Approximately 85% of lung cancers are non-small-cell lung cancers (NSCLCs), which are often diagnosed at an advanced stage and associated with poor prognosis... 
INACTIVATION | MEDICINE, RESEARCH & EXPERIMENTAL | SUPEROXIDE-DISMUTASE-1 SOD1 | ACTIVATION | NRF2 | GLUTATHIONE | ANTIOXIDANT | MITOCHONDRIA | DEATH | COPPER-BINDING | ATN-224 | Lung Neoplasms - drug therapy | Superoxide Dismutase - genetics | Humans | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Superoxide Dismutase - antagonists & inhibitors | Lung Neoplasms - pathology | Tumor Suppressor Protein p53 - genetics | MAP Kinase Signaling System | Antineoplastic Agents - pharmacology | Superoxide Dismutase - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Aniline Compounds - pharmacology | Lung Neoplasms - enzymology | Mice, Inbred C57BL | Tumor Suppressor Protein p53 - metabolism | Mice, Transgenic | Molybdenum - pharmacology | Sulfonamides - pharmacology | Cell Adhesion | Hydrogen Peroxide - metabolism | Drug Synergism | Animals | Tumor Burden - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Superoxide Dismutase-1 | Apoptosis | Drug Screening Assays, Antitumor | Antioxidants | Complications and side effects | Care and treatment | Prognosis | Development and progression | Research | Lung cancer, Non-small cell | Health aspects | Enzymes | Lung cancer | Software | Histology | Mutation | Copper | Drug dosages | Cancer therapies
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2013, Volume 19, Issue 23, pp. 6556 - 6565
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. e510 - e521
.... Research on molecular markers has revealed many potential targets for antineoplastic agents, and a particularly important aberration is translocation in the ALK gene, identified in non-small-cell lung cancer (NSCLC... 
Hematology, Oncology and Palliative Medicine | ANAPLASTIC LYMPHOMA KINASE | PROPHYLACTIC CRANIAL IRRADIATION | ONCOLOGY | BARRIER PERMEABILITY | LEPTOMENINGEAL CARCINOMATOSIS |